

2023 APEC Good Registration Management (GRM) CoE Workshop Agenda

September 6 th 2023		
Time	Topics	Affiliation/Economy
09:00-09:20	Opening Remarks	<p>Shou-Mei Wu (吳秀梅署長) Director General, Taiwan Food and Drug Administration (TFDA)</p> <p>Ayumi Endo Office Director, Office of Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs, Pharmaceuticals and Medical Devices Agency (PMDA)</p> <p>Shinji Hatakeyama Leader, Regulations and Approvals Expert Working Group (RA-EWG), APAC, and Director, Japan/Asia Regulatory & Asia Clinical Operations Department, Medicine Development Center, Eisai Co., Ltd, Japan</p>
09:20-09:35	GROUP PHOTO	
<p>Keynote Speech 1 【Moderator】 Yi-Chu Lin(林意筑專門委員), Senior Specialist, Division of Medicinal Product, TFDA</p>		
09:35-10:15	Good Review Practice and Regulatory Convergence in Accepting Global Clinical Data for Regulatory	<p>Herng-Der Chern (陳恆德醫師) Standing Director, Taiwan Society of Regulatory Affairs for</p>

	Approval	Medical Products
10:15-10:25	Q&A	
10:25-10:40	COFFEE BREAK	
Keynote Speech 2 【Moderator】 Yi-Chu Lin(林意筑專門委員), Senior Specialist, Division of Medicinal Product, TFDA		
10:40-11:20	Assessment of Global Clinical Data for Drug Approval in Europe	Aaron Sosa Mejia Medical Oncologist, Chief Medical Officer, Danish Medicines Agency (DKMA), and Alternate CHMP member for Denmark, European Medicines Agency (EMA)
11:20-11:30	Q&A	
Session 1: Introduction of GRM 【Moderator】 Mei-Chen Huang(黃玫甄簡任技正), Senior Technical Specialist, Division of Medicinal Product, TFDA		
11:40-12:00	- Concept of GRM - Objective of the training	Kuo-Teng Hung (洪國登科長) Section Chief, Division of Medicinal Product, TFDA
12:00-13:00	LUNCH TIME	
Session 2: Managing and Conducting the Review 【Moderator】 Mei-Chen Huang(黃玫甄簡任技正), Senior Technical Specialist, Division of Medicinal Product, TFDA		
13:00-13:40	An introductory overview of Managing and Conducting the Review	Yueh-Tung Tsai (蔡岳樞技正) Technical Specialist, Division of Medicinal Product, TFDA
13:40-14:20	Global Clinical Data Evaluation for Drug Approval in Japan	Kanae Ohara Coordinator, Office of Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs,

		PMDA
14:20-15:20	Current Practices for Managing and Conducting the Review of New Drug Applications in 3 Economies	Representatives from 3 economies
15:20-15:35	Panel Discussion	Yueh-Tung Tsai (蔡岳橿技正) Technical Specialist, Division of Medicinal Product, TFDA Ayumi Endo Office Director Office of Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs, PMDA Representatives from 3 economies
15:35-15:50	COFFEE BREAK	
Session 3: Regulatory Competency Framework 【Moderator】 Ming-Mei Wu(吳明美副組長), Deputy Director, Division of Medicinal Product, TFDA		
15:50-16:20	Regulatory Competency Framework: A Tool to Help Planning Professional Development and Training	Lawrence Liberti Director, The D. K. Kim International Center for Regulatory Science, University of Southern California (USC)
16:20-16:50	Rolling Out the GRM Training Program in Each Economy: Trainer's Manual	Hiroko Kawaguchi Prin. Scientist, MSD. K. K RA-EWG APAC (Japan)
16:50-17:00	Q&A	
17:30-	WELCOME BANQUET (桂華軒)	

September 7th 2023

Time	Topics	Affiliation/Economy
<p>Session 4: Planning of Application 【Moderator】 Rosa Fu Associate Director, Regulatory Affairs, Eli Lilly and Company(Taiwan), IRPMA</p>		
08:30-08:35	<u>Ice Breaker</u>	<p>【Speaker】 Finny Liu APAC Regional Regulatory Policy Lead, Roche Singapore Jocelyn Lee Director of Regulatory Affair, Senhwa Biosciences 【Facilitator】 IRPMA & TFDA/CDE Members</p>
08:35-09:25	<u>Introductory Lectures</u> - Planning of New Drug application - Planning of Generic Drug applications	
09:25-10:15	<u>Group Discussion</u> Case Studies: New Drugs & Generic Drugs	
10:15-10:30	COFFEE BREAK	
10:30-11:20	<u>Group Presentation</u> Case Studies: New Drugs & Generic Drugs	
<p>Session 5-1: Preparation of Application Dossier /Practice: How to Prepare Application Dossier 【Moderator】 Yukiko Noguchi, Associated Director, Regulatory affairs, Astellas Pharma Inc. RA-EWG APAC (Japan)</p>		
11:30-11:35	<u>Ice Breaker</u>	<p>Yukiko Noguchi Associated Director, Regulatory Affairs, Astellas Pharma Inc. RA-EWG APAC (Japan)</p>
11:35-12:15	<u>Lectures</u> - Standard process of application dossier preparation	<p>Kumiko Hikida Manager, Global Regulatory Affairs Department, Mitsubishi Tanabe Pharma Corporation,</p>

		JAPAN, RA-EWG APAC (Japan)
	- Support tools	Masaaki Kanno SP Team Lead, Overseas Regulatory Office Regulatory Affairs Department, Otsuka Pharmaceutical Co., Ltd. RA-EWG APAC (Japan)
12:15-13:10	LUNCH TIME	
<p>Session 5-2: Preparation of Application Dossier /Practice: How to Prepare Application Dossier</p> <p>【Moderator】 Shinji Hatakeyama Leader, Regulations and Approvals Expert Working Group (RA-EWG), APAC, and Director, Japan/Asia Regulatory & Asia Clinical Operations Department, Medicine Development Center, Eisai Co., Ltd, Japan</p>		
13:10-14:00	<u>Group Discussion</u> Practice: How to prepare application dossier	【Moderator】 Shinji Hatakeyama Leader, Regulations and Approvals Expert Working Group (RA-EWG), APAC, and Director, Japan/Asia Regulatory & Asia Clinical Operations Department, Medicine Development Center, Eisai Co., Ltd, Japan 【Facilitator】 IRPMA&TFDA/CDE Members
14:00-14:50	<u>Group Presentation</u> Practice: How to prepare application dossier	
14:50-15:00	COFFEE BREAK	
<p>Session 6: Communications</p> <p>【Moderator】 Min Chen(李敏珠顧問) Principal of US Pharmacovigilance LLC, and Consultant, Division of Medicinal Products, TFDA, and Former Acting Director of Division of Pharmacovigilance, Office of Surveillance and</p>		

Epidemiology, Center for Drug Evaluation and Research (CDER), US FDA

15:00-15:20	<p><u>Lectures</u></p> <p>- Good communications: Fundamentals from Regulatory Perspectives</p>	<p>Min Chen (李敏珠顧問) Principal of US Pharmacovigilance LLC, and Consultant, Division of Medicinal Products, TFDA, and Former Acting Director of Division of Pharmacovigilance, Office of Surveillance and Epidemiology, CDER, US FDA</p>
15:20-15:40	<p><u>Lectures</u></p> <p>- Overview of Communication mechanisms: Industry Aspects</p>	<p>Wimolsiri Punjatanasak Regulatory Affairs Director, MSD (Thailand) Ltd., RA-EWG APAC (Thailand)</p>
15:40-16:35	<p><u>Group Discussion</u></p>	<p>【Moderator】 Min Chen(李敏珠顧問) Principal of US Pharmacovigilance LLC, and Consultant, Division of Medicinal Products, TFDA, and Former Acting Director of Division of Pharmacovigilance, Office of Surveillance and Epidemiology, CDER, US FDA</p>
16:35-17:30	<p><u>Group Presentation</u></p>	<p>Wimolsiri Punjatanasak Regulatory Affairs Director, MSD (Thailand) Ltd., RA-EWG APAC (Thailand)</p> <p>【Facilitator】 IRPMA&TFDA/CDE Members</p>

September 8th 2023

Time	Topics	Affiliation/Economy
<p>Session 7: Critical thinking and regulatory decision-making</p> <p>【Moderator】 Jo-Feng Chi (祁若鳳研究員), Researcher, Division of Medicinal Product, TFDA</p>		
09:00-09:30	<p><u>Lectures</u></p> <p>- The Elements of Quality Regulatory Decision Making</p>	<p>Lawrence Liberti Director, The D. K. Kim International Center for Regulatory Science, University of Southern California (USC)</p>
09:30-09:50	<p><u>Lectures</u></p> <p>- Bridging Study Evaluation (How to accept foreign data): An Overview</p>	<p>Chi-Hsun Chen (陳紀勳醫師) Senior Clinical Section Chief, Center for Drug Evaluation</p>
09:50-10:05	COFFEE BREAK	
10:05-11:00	Case Studies (1/2)	<p>【Moderator】 Chi-Hsun Chen (陳紀勳醫師) Senior Clinical Section Chief, Center for Drug Evaluation</p> <p>Wei-Lun Peng (彭偉倫醫師) Senior Medical Reviewer, Division of New Drugs, Center for Drug Evaluation</p>
11:00-12:00	Case Studies (2/2)	<p>Yi-Lin, Wang (王藝琳資深審查員) Senior Reviewer, Division of Pharmaceutical Science, Center for Drug Evaluation</p> <p>【Facilitator】 IRPMA&TFDA/CDE Members</p>

12:00-13:00	LUNCH	
Keynote Speech 3 【Moderator】 Hwei-Fang Cheng(陳惠芳副署長), Deputy Director General, TFDA		
13:00-13:40	Modernizing Clinical Trials: A Focus on Decentralized Clinical Trials	M. Khair ElZarrad Director, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. FDA
13:40-13:50	Q&A	
14:00-14:30	Closing Remarks • Certificate Award Ceremony • Closing Remarks	Shou-Mei Wu (吳秀梅署長) Director General, TFDA